Abstract

Lewy body dementias such as Parkinson’s Disease are the third most common form of dementia after Alzheimer’s Disease, yet no disease-modifying therapies have been discovered. A hallmark of these conditions is the accumulation of misfolded protein deposits in the brain. However, the role of these aggregates in causing disease and accelerating its progression are poorly understood. The goal of this application is to develop small molecules that selectively clear these proteins, and evaluate them as potential therapeutics.